Clinical trial
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning…
NCT00209508 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00209508 |
|---|---|
| Title | 2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy. |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Symphony Neuro Development Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | GPI 1485 |
| Enrollment | 200 |
| Start date | Nov 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 7, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: